MetaGenX™ is an advanced metabolic modeling and whole-body simulation platform designed to address the complex needs of drug development and precision medicine. By accurately simulating how drugs interact with various tissues and biological systems, MetaGenX™ empowers pharmaceutical companies to predict drug efficacy, toxicity, and patient-specific responses across different metabolic environments. This platform is indispensable for identifying potential side effects, optimizing combination therapies, and tailoring treatments to individual patients—ensuring higher success rates in clinical trials and more effective, targeted therapies in the market.

Early prediction of side effects

Reliable approaches for early prediction of drug side effects are clearly needed, and they would benefit from systems analysis platforms that are broadly predictive across human cell types and tissues.

Our Solution: An attractive system for such broad-scale analyses is cellular metabolism, which is a critical actor in many human diseases and phenotypes. Metabolism is the only genome-wide network to be reliably converted into predictive models. MetaGenX™ provides detailed simulations of how potential drug candidates interact with various biological systems. This enables the identification of off-target effects and potential toxicity, thereby improving the selection of viable candidates before they enter clinical trials.

Drug efficiency and toxicity across different tissues and individuals

Drug efficacy can vary significantly based on tissue-specific metabolic environments and individual patient differences.

Our Solution: MetaGenX™ metabolic models allow for the simulation of drug action across different tissues, helping to predict how a drug’s effects might differ depending on where it’s metabolized. By integrating patient-specific data (e.g., different metabolic patterns of cancer cells), these models can personalize predictions, identifying which individuals are likely to respond better or experience resistance, thus guiding precision medicine approaches and optimizing dosing strategies across diverse patient populations. For example, Metabolic heterogeneity is a hallmark of cancer and can distinguish a normal phenotype from a cancer phenotype. MetaGenX™ leverages different patterns of metabolic heterogeneity across various cancer types. It leads to precision medicine, and lowering risk of clinical trials.

Resistance Mechanism Identification and Optimization of Drug Design

Cells often activate compensatory pathways when one metabolic route is blocked by drugs. (e.g., kinase inhibitors)

Our Solution: MetaGenX™ solves it by Combinatorial therapy and Drug candidates optimization.

MetaGenX™ can explore how combining inhibitors with other drugs impacts metabolic pathways. For example, if Wnt in drugs block one metabolic route, it shifts tumor metabolism toward increased reliance on glutamine in some individuals (considering personalized metabolism pattern), the model could suggest combining the inhibitor with a glutaminase inhibitor.

Biomarker discovery

Translating in vitro biomarker predictions to in vivo settings to estimate clinical trial drug delivery and efficiency.

Our Solution: Identifying metabolic biomarkers for early detection of drug response and safety profiling in clinical trials by MetaGenX™ whole-body models could be an option. Predicting how systemic metabolism might influence the levels and detectability of these biomarkers in blood or other accessible fluids to track drug delivery and impact.

Market Preparation and Patient Stratification

As Phase 3 trials conclude, preparing for market launch requires a deep understanding of how the drug will be received by different patient groups. Stratifying patients to identify those who will benefit most from the drug is essential for guiding clinical use and marketing strategies.

Our Solution: MetaGenX™ facilitates patient stratification by predicting which subpopulations are most likely to benefit from the drug based on their metabolic profiles. This information can be used to develop targeted treatment guidelines and personalized medicine approaches, ensuring that the drug is used effectively in the market. Additionally, the platform’s simulations can inform marketing strategies by identifying key patient demographics and predicting drug uptake and success in real-world settings.

Drug Sensitivity, Diet Design, and Adaptive Monitoring

Drug sensitivity varies among patients due to differences in genetic makeup, metabolic pathways, and lifestyle factors like diet. These variations can impact drug efficacy and safety, potentially leading to suboptimal outcomes in clinical trials. Additionally, the dynamic interaction between diet and drug metabolism during trials can cause variability in patient responses.

Our Solution: MetaGenX™ addresses these challenges by integrating metabolic modeling with patient-specific data, including genetic and dietary information. This enables the prediction of drug sensitivity, allowing for personalized treatment plans that enhance efficacy and minimize side effects. The platform also incorporates diet design into its modeling, identifying optimal diet-drug combinations that improve therapeutic outcomes. Furthermore, MetaGenX™ provides real-time adaptive monitoring, allowing for continuous adjustments to dietary recommendations based on patient responses, ensuring consistent efficacy and safety throughout the trial.

Importantly, MetaGenX™ leverages microbiome metabolism and a comprehensive digestive system simulation.

High Costs of Drug Development and Clinical Trials

Drug development and clinical trials are notoriously expensive, often requiring substantial financial investments to gather and analyze large amounts of data, recruit participants, and conduct extensive testing. The high costs can be prohibitive, especially for exploring new drug candidates or studying complex conditions. Traditional methods involve significant expenses related to patient recruitment, sample collection, and extensive lab work, which can delay timelines and strain budgets.

Our Solution: MetaGenX™ addresses this challenge by leveraging advanced metabolic modeling to simulate drug interactions and predict outcomes without the need for extensive real-world data collection. By generating detailed simulations and insights for drug candidates, the platform reduces the need for further costly patient recruitment and lab experiments. This cost-effective approach enables faster, more affordable exploration of drug candidates and streamlines the drug development process, ultimately saving time and resources while accelerating progress.

Set appointment for more information?